Discovery of Novel Chemotype LRRK2 Inhibitors Through AlphaFold2-Generated Structure-Based Docking Screen
International Journal of Molecular Sciences · 09.04.2026 · 27 (8) · 3391
DOI: 10.3390/ijms27083391 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.04.2026. Verfasst von Rishiram Baral und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Molecular Docking Simulation, Protein Kinase Inhibitors, Drug Discovery. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Ministry of Oceans and Fisheries, Korea Basic Science Institute.
Abstract (Originalsprache)
The structures predicted by AlphaFold can provide unprecedented opportunities for docking screens; however, experimentally validated examples of using the apo-form are limited. This study reports novel chemotype inhibitors targeting the leucine-rich repeat kinase 2 (LRRK2) kinase domain through a docking screen using one of the ensemble structures starting from the template deposited by AlphaFold2. The MODELLER software generated the ensemble. The conformer that showed the best early enrichment of true positives with the mixture of known ligands and their property-matched decoys was selected. The docking screen against approximately 1.3 million small molecules and enzyme-based assays with the LRRK2 kinase domain followed. We selected 17 molecules, excluding those similar to all known kinase inhibitors. Combined with analogs-by-catalog, ten new small molecules with Ki values below 15 μM were discovered, including one sub-μM inhibitor. To test selectivity, enzyme assays with a mutant and six additional kinases, including known off-targets of existing LRRK2 inhibitors, were performed using three inhibitors. The data suggest that the novelty in chemical structure may be insufficient for providing selectivity. Our approach is generally applicable to cases where information on known binders is available but experimental structure is not.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.
ORCID-Profile: Rishiram Baral
Förderung
- Ministry of Education
- Ministry of Oceans and Fisheries
- Korea Basic Science Institute
Zitieren
APA
Baral, R., Lee, J. I., & Jee, J. G. (2026). Discovery of Novel Chemotype LRRK2 Inhibitors Through AlphaFold2-Generated Structure-Based Docking Screen. International Journal of Molecular Sciences, 27(8), 3391. https://doi.org/10.3390/ijms27083391
Vancouver
Baral R, Lee JI, Jee JG. Discovery of Novel Chemotype LRRK2 Inhibitors Through AlphaFold2-Generated Structure-Based Docking Screen. International Journal of Molecular Sciences. 2026;27(8):3391. doi:10.3390/ijms27083391
BibTeX
@article{Baral2026,
author = {Baral, Rishiram and Lee, Jeong In and Jee, Jun-Goo},
title = {Discovery of Novel Chemotype LRRK2 Inhibitors Through AlphaFold2-Generated Structure-Based Docking Screen},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {8},
pages = {3391},
doi = {10.3390/ijms27083391}
}
EUVIMED